Gene therapy trial offers new hope for lymphoma patients who have run out of options
NCT ID NCT07211048
Summary
This early-stage study is testing a new gene-based treatment called LCAR02 for people with B-cell lymphoma that has come back or not responded to standard treatments. The main goals are to check if the treatment is safe and to see if it helps shrink tumors. Up to 18 participants will receive the treatment, which involves an injection of genetically modified cells designed to target and fight their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, Anhui, 230001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.